Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · USD

$14.8

+0.25 (+1.7%)· Recorded snapshot

Market cap	6.7B
Revenue (ttm)	325M
Net income (ttm)	-289.5M
EPS (ttm)	-$0.71
Shares out	453M
Volume	7,684,976
Beta	0.76

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 325M
Net income (ttm): -289.5M
EPS (ttm): -$0.71
Market cap: 6.7B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-40.4

P25 n/aP50 n/aP75 n/a

ROIC-24.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All IOVA indicators

Market & fundamental data

Available fields

217

Groups with data

Currency

USD

Showing 217 of 217 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001425205
Company name	Iovance Biotherapeutics, Inc.
Country	United States
Country code	US
CUSIP number	462260100
Earnings date	2026-11-05
Earnings time	bmo
Employees	975
Employees change	137
Employees growth	16.35%
Enterprise value	$6.5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2007
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US4622601007
Last 10-K release date	2026-02-24
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2013-09-26
Last stock split type	Reverse
Market cap	$6.7B
Market cap category	Mid-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$14.83
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	IOVA
U.S. state	California
Website	https://www.iovance.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-4.76%
EV/Sales	19.91x
FCF / EV yield	-4.58%
FCF yield	-4.41%
Forward EV/Sales	12.4x
Forward P/S	12.89x
P/B ratio	8.97x
P/S ratio	20.69x
Price / tangible book value	14.24x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-91.14%
EBITDA margin	-79.89%
Gross margin	48.4%
Operating margin	-91.14%
Pretax margin	-90.4%
Profit margin	-89.09%
Profit per employee	$-296,941
Revenue per employee	$333,302
ROA	-20.31%
ROA (5Y)	-31.74%
ROCE	-36.62%
ROE	-40.36%
ROE (5Y)	-63.81%
ROIC	-24.14%
SBC / revenue	14.38%
Tax / revenue	-1.31%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	14
EPS growth years	3
Gross profit growth	65.03%
Gross profit growth (Q)	403.28%
Net income growth quarters	3
Net income growth years	0
Revenue growth	34.55%
Revenue growth (Q)	65.65%
Revenue growth (QoQ)	39.04%
Revenue growth 3Y	1,009.4%
Revenue growth quarters	9
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-32.2M
Depreciation and amortization	$36.6M
EBIT	$-296.2M
EBITDA	$-259.6M
EPS	$-0.71
FCF per share	$-0.65
Financing cash flow	$287.9M
Free cash flow	$-296.4M
Free cash flow minus SBC	$-343.1M
Gross profit	$157.3M
Income taxes	$-4.3M
Investing cash flow	$-44.9M
Net cash flow	$-21.6M
Net income	$-289.5M
Operating cash flow minus SBC	$-310.9M
Operating income	$-296.2M
Revenue	$325M
Stock-based compensation	$46.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-0.81
Book value per share	$1.62
Debt / equity	0.06
Long-term assets	$451.3M
Long-term liabilities	$72.6M
Net cash (debt)	$251.7M
Net cash / market cap	3.74%
Net cash growth	1.47%
Net debt / equity	-0.34
Piotroski F-Score	4
Property, plant and equipment	$174.9M
Shareholders' equity	$736M
Tangible book value	$472.1M
Tangible book value per share	$1.04
Total assets	$915.5M
Total cash	$297.7M
Total debt	$46M
Total liabilities	$179.5M
WACC	8.35%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.36
Current assets	$464.3M
Current liabilities	$106.8M
Current ratio	4.35
Inventory turnover	3.18
Net working capital	$62.4M
Quick ratio	3.74
Working capital	$357.4M
Working capital turnover	1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-29.62%
Dividend yield	0%
Shareholder yield	-29.62%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	144.5%
10Y return CAGR	9.35%
10Y total return	144.5%
150-day SMA	$6.60
15Y price change	-88.54%
15Y return CAGR	-13.45%
15Y total return	-88.54%
1D price change	1.71%
1M price change	33.36%
1M total return	33.36%
1W price change	-1.28%
1W total return	-1.28%
1Y price change	535.07%
1Y return CAGR	535.87%
1Y total return	535.07%
20-day SMA	$14.15
200-day SMA	$5.77
3M price change	199.39%
3M total return	199.39%
3Y price change	319.14%
3Y return CAGR	61.22%
3Y total return	319.14%
50-day SMA	$11.35
50-day SMA vs 200-day SMA	50over200
52-week high	$15.37
52-week high date	2026-10-21
52-week low	$1.76
52-week low date	2025-11-05
5Y price change	-42.43%
5Y return CAGR	-10.46%
5Y total return	-42.43%
6M price change	327.7%
6M total return	327.7%
After-hours change	-0.54%
After-hours close	$14.83
After-hours price	$14.75
All-time high	$165.00
All-time high date	2011-06-07
All-time low	$1.01
All-time low date	2013-05-03
Average true range (ATR)	$0.90
Average volume	11.5M
Beta (1Y)	1.11
Beta (2Y)	1.43
Beta (5Y)	0.76
Change from 52-week high	-3.51%
Change from 52-week low	742.61%
Change from all-time high	-91.11%
Change from all-time low	1,352.48%
Change from open	3.42%
Day's gap	-1.65%
Dollar volume	$114M
High price	$14.90
Low price	$14.20
Monthly RSI	72.59
Open price	$14.34
Position in 52-week range	90%
Premarket change	-1.23%
Premarket close	$14.58
Premarket price	$14.40
Premarket volume	112.2K
Previous close	$14.58
Price vs 150-day SMA	122.14%
Price vs 20-day SMA	3.69%
Price vs 200-day SMA	154.29%
Price vs 50-day SMA	29.29%
Relative volume	0.67
RSI	62.18
Sharpe ratio	2.21
Sharpe ratio (3Y)	0.93
Sharpe ratio (5Y)	0.32
Sortino ratio	4.81
Sortino ratio (3Y)	1.63
Sortino ratio (5Y)	0.56
Volume	7.7M
Weekly RSI	81.52
YTD price change	437.36%
YTD total return	437.36%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	394.3M
Float percentage	87.05%
Shares change (QoQ)	7.57%
Shares change (YoY)	29.62%
Shares held by insiders	6.56%
Shares held by institutions	58.01%
Shares outstanding	453M
Short % of float	14.94%
Short % of shares	13.01%
Short ratio	3.3 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	263

Deeper analysis on IOVA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IOVA report

Is a complete IOVA research report available?

No complete published report is available for Iovance Biotherapeutics, Inc. (IOVA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Iovance Biotherapeutics, Inc. (IOVA)

Price

Financial snapshot

Fair-value bridge

Latest news · IOVA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IOVA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on IOVA

Frequently asked questions